Detalhe da pesquisa
1.
Organoid Modeling of the Tumor Immune Microenvironment.
Cell
; 175(7): 1972-1988.e16, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30550791
2.
The Value and Process of Inclusion: Using Sensitive, Respectful, and Inclusive Language and Images in NCCN Content.
J Natl Compr Canc Netw
; 21(5): 434-441, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156485
3.
Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study.
Oncologist
; 27(9): 751-759, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35589098
4.
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Invest New Drugs
; 40(6): 1306-1314, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264382
5.
177Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1752-1763, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793718
6.
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
Oncologist
; 26(11): 950-955, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34342086
7.
Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
Oncologist
; 25(2): e276-e283, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043766
8.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076709
9.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32123969
10.
Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
J Natl Compr Canc Netw
; 18(9): 1200-1209, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886901
11.
Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.
Curr Treat Options Oncol
; 21(4): 25, 2020 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32172368
12.
Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.
Eur J Nucl Med Mol Imaging
; 46(11): 2244-2251, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350603
13.
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
J Natl Compr Canc Netw
; 16(6): 693-702, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29891520
14.
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour.
Eur Respir J
; 59(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34795035
15.
Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age.
Lancet Oncol
; 21(11): 1395-1397, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152282
16.
Role of somatostatin analogues in the treatment of neuroendocrine tumors.
J Natl Compr Canc Netw
; 13(1): 109-17; quiz 117, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25583773
17.
Neuroendocrine tumors, version 1.2015.
J Natl Compr Canc Netw
; 13(1): 78-108, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25583772
18.
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
J Neurooncol
; 123(2): 277-82, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25935109
19.
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Clin Adv Hematol Oncol
; 13(5 Suppl 5): 1-18; quiz 1 p following 18, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26430956
20.
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.
HPB (Oxford)
; 16(4): 304-11, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23991643